Navigation Links
Second-most common breast cancer subtype may benefit from personalized treatment approach
Date:2/25/2014

PITTSBURGH, Feb. 26, 2014 The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

Invasive lobular carcinoma, which is characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers that indicate there may be benefits from drug therapies beyond those typically prescribed for the more common invasive ductal carcinoma. The results will be published in the March 1 issue of the journal Cancer Research.

Patients with invasive lobular carcinoma are typically treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.

"However, recent analyses have shown that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said senior author Steffi Oesterreich, Ph.D., professor at UPCI, a partner with UPMC CancerCenter, and director of education at the Women's Cancer Research Center. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to a potential target for drug therapy in future clinical trials, which we are developing."

The UPCI study, funded by the Breast Cancer Research Foundation and the U.S. Department of Defense, included collaborations across multiple disciplines, ranging from biostatistics and biomedical informatics to pathology and human genetics, in order to produce results with the potential for rapid translation into clinical therapies.

"In addition to its potential clinical implications, the study highlights the need for more and bette
'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Finding common ground fosters understanding of climate change
2. Common crop pesticides kill honeybee larvae in the hive
3. Arctic cyclones more common than previously thought
4. How common is aggression in UK dogs?
5. Walking the walk: What sharks, honeybees and humans have in common
6. Study of rodent family tree puts brakes on commonly held understanding of evolution
7. Human error most common cause of birth asphyxia
8. Gene linked to common intellectual disability
9. Model virus structure shows why theres no cure for common cold
10. Common bias known as the endowment effect not present in hunter-gatherer societies
11. OU research team finds a common bioindicator resistant to insecticides
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Second-most common breast cancer subtype may benefit from personalized treatment approach
(Date:7/10/2014)... 10, 2014Women in the West African nation Burkina ... planning option. Sayana Press has the potential to ... the health system and in communities by combining ... Depo-Provera (depot medroxyprogesterone acetate)with the BD Uniject injection ... four African countries expected to begin introducing Sayana ...
(Date:7/9/2014)... Caesarean section have a different intestinal flora than children delivered ... is the case and what it means for the immune ... therefore decided to scrutinise the impact of birth on the ... mouse pups. , The study shows that ... of cells that strengthen the immune system, says Camilla Hartmann ...
(Date:7/9/2014)... hunts in Indiana state parks have helped restore the ... by overabundant populations of white-tailed deer, a Purdue study ... associate professor of forest ecology, found that a 17-year-long ... in state parks has successfully spurred the regrowth of ... browsing deer. , Jenkins said that while hunting ...
Breaking Biology News(10 mins):Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3Mouse study: Natural birth may strengthen the immune system 2Hunting gives deer-damaged forests in state parks a shot at recovery 2
... in the Canadian Rockies are stifling the mating choices ... researchers. , Smaller and less abundant alpine meadows--largely the ... pool, creating a pattern that could lead to the ... Roland, a biological scientist at the University of Alberta ...
... and bitter tastes may reside in the same taste bud ... discovery of a chemical messenger called neuropeptide Y (NPY) in ... is active in the brain and gut, this is the ... taste bud cells. , That finding gives scientists a deeper ...
... which is involved in cellular immune signaling, scientists have succeeded ... This old protein with a new twist may eventually be ... Stat1 is involved in immune responses that are initiated by ... cells of the immune system in response to challenges by ...
Cached Biology News:Expanding forests darken the outlook for butterflies, study shows 2Bitter or sweet? The same taste bud can tell the difference 2Bitter or sweet? The same taste bud can tell the difference 3Engineered molecule amplifies body's immune response 2Engineered molecule amplifies body's immune response 3
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 2011 CryoLife, Inc. (NYSE: CRY ), an ... today that it has filed an IDE with ... clinical trials for the purpose of obtaining Pre-Market Approval (PMA) ... surgical procedures or following traumatic injuries. PerClot ...
... 2011 Orexigen ® Therapeutics, Inc. (Nasdaq: ... showed that overweight and obese patients treated with ... 24-hour circadian patterns over one year of treatment. ... monitoring (ABPM) sub-study of the COR-II trial that ...
... OMER ), a biopharmaceutical company committed to ... and disorders of the central nervous system, today announced ... officer, is scheduled to present at the 10th Annual ... this week.  The presentation is scheduled for Tuesday, April ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
...
... T4 DNA Ligase catalyzes the formation ... ATP between double-stranded DNAs with 3' hydroxyl ... DNA Ligase buffer optimizes ligation which can ... nucleic acids are not substrates for this ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Biology Products: